Neuronetics, Inc. (STIM) News
Filter STIM News Items
STIM News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
STIM News Highlights
- For STIM, its 30 day story count is now at 21.
- Over the past 25 days, the trend for STIM's stories per day has been choppy and unclear. It has oscillated between 1 and 3.
- AMP, DRUG and ICD are the most mentioned tickers in articles about STIM.
Latest STIM News From Around the Web
Below are the latest news stories about NEURONETICS INC that investors may wish to consider to help them evaluate STIM as an investment opportunity.
Walgreens Boots (WBA) Gains From New Alliances Amid Macro WoesContinued slowdown in generic introduction has been affecting Walgreens Boots' (WBA) margins. |
Neogen (NEOG) Introduces 2 Assays for Histamine DetectionNeogen (NEOG) launches Reveal for Histamine and Reveal Q+ for Histamine assays for the detection of Histamine. |
LabCorp (LH) Expands Precision Oncology With Biopsy TestThe addition of Labcorp Plasma Focus marks a pivotal step in the expansion of LabCorp's (LH) suite of precision oncology tests. |
Illumina (ILMN) to Present Real-World CGP Data at ASCO Meet '23At the ASCO meeting, Illumina (ILMN) is set to showcase data that highlights better outcomes for cancer patients who receive comprehensive genomic testing. |
Medtronic's (MDT) EV ICD Pivotal Study Shows Favorable Outcome (Revised)Medtronic (MDT) announces that the findings of the EV ICD Pivotal Study reinforce device safety and effectiveness. |
Neuronetics Announces Increased TMS Access Through BlueCross BlueShield Of MichiganLower Medication Requirement Helps Depression Patients Obtain Treatment SoonerMALVERN, Pa., May 26, 2023 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders, today announced a healthcare policy update from BlueCross BlueShield (BCBS) of Michigan that expands eligibility for depression patients to receive transcranial magnetic |
Myriad Genetics (MYGN) Adds New Test to Oncology PortfolioMyriad Genetics (MYGN) expands Precise Oncology Solutions portfolio by adding a new biomarker test. |
Neuronetics to Present at the William Blair 43rd Annual Growth Stock ConferenceMALVERN, Pa., May 24, 2023 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM) (the “company” or “Neuronetics”), a commercial stage medical technology company with a strategic vision of transforming the lives of patients whenever and wherever they need help with the best neurohealth therapies in the world, announced that the management team will present at the William Blair 43rd Annual Growth Stock Conference on Wednesday, June 7, 2023. The Company is scheduled to present at 1:00 pm Eastern Tim |
Medtronic's (MDT) EV ICD Pivotal Study Shows Favorable OutcomeMedtronic (MDT) announces that the findings of the EV ICD Pivotal Study reinforce device safety and effectiveness. |
Exact Sciences (EXAS) Gains From New Buyouts Amid High CostsFollowing the acquisitions of Paradigm and Ashion, Exact Sciences (EXAS) is now offering therapy selection tests for patients with advanced cancer. |